Trevi Therapeutics, Inc.
TRVIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary. With a market capitalization of $2.46B, it sits in mid-cap territory. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Market Cap
$2.46B
Beta
1.05
P/E (TTM)
—
P/E (Fwd)
-29.91
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.58
ROE
-19.7%
ROA
-13.8%
Cash
$318.9M
Total Debt
$605,000
Free CF
-$33.3M
52W Change
124.5%
Annual Financials
Cash vs Debt
Where TRVI stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, TRVI finished 26.17% above its 150-day moving average ($14.33) and 31.30% above its 200-day moving average ($13.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TRVI overbought or oversold?
At the August 25, 2026 close, TRVI's RSI(14) was 39.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Trevi Therapeutics, Inc. holds $318.9M in cash against $605K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$33.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -19.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TRVI.